No­var­tis finds a third-gen­er­a­tion scion to an ag­ing Gleevec, suc­cess­ful­ly tak­ing on a Pfiz­er ri­val for last-chance CML pa­tients

Near­ly 20 years af­ter No­var­tis’ fad­ing block­buster Gleevec trans­formed the treat­ment of chron­ic myeloid leukemia and in­spired a wave of new treat­ments to fol­low, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER